175140-03-1

Upstream product

• 88-05-1 2,4,6-trimethylaniline 
• 175140-65-5 (2-chloro-6-methyl-3-nitro-pyridin-4-yl)-(1-ethyl-propyl)-amine 

Downstream Products

• 175140-07-5 N₄-(1-ethyl-propyl)-6-methyl-N₂-(2,4,6-trimethyl-phenyl)-pyridine-2,3,4-triamine 

Relevant academic research and scientific papers

Corticotropin releasing factor antagonists

Corticotropin-releasing factor (CRF) antagonists having the formulae wherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16 and R17 are as defined in the application, and processes fo

CRF receptor antagonists and methods relating thereto

Compounds are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, including stroke. The compounds of this invention have the following structures: wherein n, m, R, R1, R2, X and Ar are as defined herein, including stereoisomes and pharmaceutically acceptable salts thereof.

Use of CRF antagonists and renin-angiotensin system inhibitors

The present invention relates to compositions and methods of achieving a therapeutic effect including, but not limited to, the treatment of congestive heart failure or hypertension in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist and a renin-angiotensin system (RAS) inhibitor.

QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death

A method of preventing sudden death which comprises administering to a mammal, including a human, a therapeutically effective amount of a corticotropin releasing factor antagonist.

New uses for corticotropin releasing factor antagonists

A method of treating, preventing or inhibiting a disorder selected from the group consisting of cardiovascular or heart related diseases such as stroke, hypertension, tachycardia, and congestive heart failure, osteoporosis, premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus, and colonic hypersensitivity associated with psychopathological disturbance and stress, comprising administering to a mammal, including a human, in need of such treatment a therapeutically effective amount of a compound of the formula or pharmaceutically acceptable salt thereof, wherein A, B, D, E, Y, Z, R3, R4, and R5 are as defined herein.

CORTICOTROPIN RELEASING FACTOR ANTAGONISTS

Corticotropin-releasing factor (CRF) antagonists having formulae (I), (II) or (III) wherein the dashed lines, A, B, Y, Z, G, R. sub.3, R. sub.4, R. sub.5, R 6, R 16 and R 17 are as defined in the description, and processes for preparing them. These compou